Allan Levey

Dec 21, 2024 | alzres.biomedcentral.com | Qiong Wang |Chenxi Wang |Feng Gao |Jiong Shi |Allan Levey |Yong Shen | +4 more

All participants of the study were recruited from a single cohort, the China Aging and Neurodegenerative Initiative (CANDI) [28] from the First Affiliated Hospital of USTC, which was supported by the Chinese Academy of Sciences.

Dec 14, 2023 | sciencemag.org | Lijia Li |Frances Spragge |Allan Levey

PerspectiveNeurodegenerationAntibodies targeting amyloid-β aggregates slow decline in Alzheimer’s diseaseThree monoclonal antibodies—aducanumab, lecanemab, and donanemab— that target amyloid-β (Aβ) deposits in the brain slow cognitive and functional decline in early Alzheimer’s disease (AD) (1–3). The data from the phase 3 clinical trials in mildly symptomatic individuals with AD demonstrate that Aβ reduction has modest clinical benefit.